Moderna, Inc. (MRNA) vs Roivant Sciences Ltd. (ROIV)
- Moderna, Inc. MRNA 218.01 −7.82%
- Roivant Sciences Ltd. ROIV 33.53 −1.50%
Moderna, Inc. and Roivant Sciences Ltd. are both Biotechnology companies. Moderna, Inc. is the larger, with a market value of $94.4B against $24.6B — 3.8× the size. Moderna, Inc. grew revenue faster over the last twelve months: −27.6% against −67.6%. Moderna, Inc. has the higher net margin (−141.4% vs −3,535.0%) and the lower return on invested capital (−93.5% vs −34.5%). Across the 18 metrics below, Moderna, Inc. leads on 10 and Roivant Sciences Ltd. on 8.
Valuation
Profitability
| Metric | MRNA | ROIV | Biotechnology median |
|---|---|---|---|
| Gross margin | 23.38% | 81.21% | 65.16% |
| Operating margin | (149.01%) | (7,914.75%) | 0.00% |
| Net margin | (141.43%) | (3,534.96%) | 0.00% |
| Free cash flow margin | (55.83%) | (10,901.00%) | 0.00% |
| Return on equity | (39.00%) | (5.47%) | (56.36%) |
| Return on assets | (27.43%) | (5.15%) | (48.04%) |
| Return on invested capital | (93.47%) | (34.51%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack